| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.16 | 4e-06 |
| mRNA | Bleomycin | GDSC1000 | pan-cancer | AAC | 0.17 | 6e-06 |
| mRNA | SGC0946 | GDSC1000 | pan-cancer | AAC | 0.16 | 2e-05 |
| mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | -0.15 | 3e-05 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-05 |
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | 0.15 | 6e-05 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | 0.12 | 7e-05 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.15 | 7e-05 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0002 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0003 |